Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)

被引：10
|
作者：
Nicum, S. [1 ]
Holmes, J. [2 ]
McGregor, N. [3 ]
Dunn, R. [3 ]
Collins, L. [3 ]
Kaye, S. [4 ]
McNeish, I. [5 ]
Glasspool, R. M. [6 ,7 ]
Hall, M. [8 ]
Roux, R. [1 ]
Michael, A. [9 ]
Banerjee, S. [10 ]
Kristeleit, R. [11 ,12 ]
Jayson, G.
Clamp, A. [13 ,14 ]
Mansouri, A. [2 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England
[2] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Ctr Stat Med CSM, Oxford Clin Trials Res Unit, Oxford, England
[3] Univ Oxford, Dept Oncol, Oncol Clin Trials Off, Oxford, England
[4] Royal Marsden Hosp, Dept Med, Sutton, Surrey, England
[5] Imperial Coll London, Dept Surg & Canc, Ovarian Canc Act Res Ctr, London, England
[6] Univ Glasgow, Beatson West Scotland Canc Ctr, NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland
[7] Univ Glasgow, Glasgow, Lanark, Scotland
[8] Mt Vernon Canc Ctr, Dept Med Oncol, Middlesex, England
[9] Univ Surrey, Dept Clin & Expt Med, Surrey, England
[10] Royal Marsden NHS Fdn Trust, Res Lead Gynaecol Unit, London, England
[11] Guys & St Thomas NHS Fdn Trust, UCL Canc Inst, London, England
[12] Guys & St Thomas NHS Fdn Trust, UCLH Dept Oncol, London, England
[13] Univ Manchester, Christie NHS Fdn Trust, Manchester Canc Res Ctr, Manchester, Lancs, England
[14] Univ Manchester, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1165
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
722O
引用
收藏
页码：S725 / S726
页数：2
相关论文
共 50 条
  • [31] WEEKLY PACLITAXEL-CARBOPLATINUM IS EFFECTIVE IN PLATINUM-RESISTANT OVARIAN CANCER PATIENTS AFTER PREVIOUS WEEKLY PACLITAXEL
    Concin, N.
    Salihi, R.
    Lage, T.
    Van Nieuwenhuysen, E.
    Neven, P.
    Vergote, I.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 664 - 664
  • [32] OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel plus /- novel agents in platinum-resistant ovarian cancer-Vistusertib (AZD2014).
    Banerjee, Susana N.
    Lewsley, Liz-Anne
    Clamp, Andrew R.
    Gabra, Hani
    Herbertson, Rebecca
    Green, Clare
    Orbegoso, Cecilia
    Wilson, Cheryl
    Banerji, Udai
    Hanif, Aishah
    McNeish, Iain A.
    Paul, James
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or - Refractory Ovarian Cancer
    Liu, Joyce F.
    Ray-Coquard, Isabelle
    Selle, Frederic
    Poveda, Andres M.
    Cibula, David
    Hirte, Hal
    Hilpert, Felix
    Raspagliesi, Francesco
    Gladieff, Laurence
    Harter, Philipp
    Siena, Salvatore
    del Campo, Josep Maria
    Tabah-Fisch, Isabelle
    Pearlberg, Joseph
    Moyo, Victor
    Riahi, Kaveh
    Nering, Rachel
    Kubasek, William
    Adiwijaya, Bambang
    Czibere, Akos
    Naumann, R. Wendel
    Coleman, Robert L.
    Vergote, Ignace
    MacBeath, Gavin
    Pujade-Lauraine, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4345 - +
  • [34] Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
    Zweifel, M.
    Jayson, G. C.
    Reed, N. S.
    Osborne, R.
    Hassan, B.
    Ledermann, J.
    Shreeves, G.
    Poupard, L.
    Lu, S. -P.
    Balkissoon, J.
    Chaplin, D. J.
    Rustin, G. J. S.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (09) : 2036 - 2041
  • [35] Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
    Tang, Sangsang
    Shen, Yuanming
    Wei, Xinyi
    Shen, Zhangjin
    Lu, Weiguo
    Xu, Junfen
    [J]. CELL DEATH & DISEASE, 2022, 13 (09)
  • [36] Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
    Sangsang Tang
    Yuanming Shen
    Xinyi Wei
    Zhangjin Shen
    Weiguo Lu
    Junfen Xu
    [J]. Cell Death & Disease, 13
  • [37] A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.
    Lheureux, Stephanie
    Alqaisi, Husam
    Cohn, David E.
    Chern, Jing-Yi
    Duska, Linda R.
    Jewell, Andrea
    Corr, Bradley
    Winer, Ira Seth
    Girda, Eugenia
    Crispens, Marta A.
    Dhani, Neesha C.
    Grant, Robert C.
    Uthayakumaran, Saranya
    Lee, Crystal
    Bowering, Valerie
    Wong, Horace
    Wang, Lisa
    Bedard, Philippe L.
    Moscow, Jeffrey
    Oza, Amit M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer.
    Wenham, Robert Michael
    Apte, Sachin M.
    Shahzad, Mian M.
    Lee, Jae K.
    Dorman, Denise
    Chon, Hye Sook
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, R. E.
    Childs, J.
    Higgins, D.
    Gooley, T.
    Goff, B. A.
    Fintak, P. A.
    Buening, B.
    Disis, M. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Roque, Dana M.
    Siegel, Eric R.
    Buza, Natalia
    Bellone, Stefania
    Silasi, Dan-Arin
    Huang, Gloria S.
    Andikyan, Vaagn
    Clark, Mitchell
    Azodi, Masoud
    Schwartz, Peter E.
    Rao, Gautam G.
    Reader, Jocelyn C.
    Hui, Pei
    Tymon-Rosario, Joan R.
    Harold, Justin
    Mauricio, Dennis
    Zeybek, Burak
    Menderes, Gulden
    Altwerger, Gary
    Ratner, Elena
    Santin, Alessandro D.
    [J]. BRITISH JOURNAL OF CANCER, 2022, 126 (12) : 1695 - 1703
12345